The move to value-based payments in Medicare needs refinement to recognize the value of medical technology, a key medical device industry group said.
The problem with the current system, the Advanced Medical Technology Association said in a report issued Dec. 19, is inadequate measures of quality that underpin this payment system can mean patients aren’t getting optimum care and costs may be the key driver, not patient outcomes.
“This study underscores the uneven playing field on which medical technology is judged, potentially depriving American patients of the innovative care they deserve,” Scott Whitaker, president and CEO of the group, said in an accompanying statement.
AdvaMed said quality measures are essential to VBP as the health system moves away from paying based on volume. The industry group said the lack of certain quality measures for device use and data collection can lead to overuse or underuse of devices and services, safety issues, and stifled innovation. AdvaMed said examples of what it called quality measure gaps exist for common procedures such as hip and knee implants, glucose monitoring, and remote patient monitoring.
The industry group wants the Centers for Medicare & Medicaid Services to add quality measures that reflect the value of medical technology in what it called “payer-developed core measure sets,” referring to health insurers. Other parts of the health-care industry should work with device makers to find and close existing gaps, AdvaMed said.
Don May, executive vice president at the device trade group, which represents 80 percent of medical technology companies in the U.S., told me the gaps exist because quality measure developers haven’t looked at the “device angle.”
Thomas Beimers, a health-care attorney at Hogan Lovells’s Minneapolis office, told me that payers, like insurance companies and the CMS, are driving value-based payments and everyone in the health-care industry is starting to get on board, including device makers.
Read my full article here.
Stay on top of new developments in health law and regulation, and learn more, by signing up for a free trial to Bloomberg Law.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)